Inovio Pharmaceuticals (INO) EBT (2010 - 2026)

Inovio Pharmaceuticals has disclosed EBT across 17 years of filings, most recently posting -$18.3 million for Q2 2026.

• In Q2 2026, EBT rose 18.75% year-over-year to -$18.3 million; the TTM figure through Jun 2026 stood at -$77.9 million (up 16.48% YoY), while the FY2025 annual figure was -$84.4 million, up 21.71% from the prior year.
• EBT came in at -$18.3 million for Q2 2026 at Inovio Pharmaceuticals, up from -$21.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$17.0 million in Q4 2025 to a low of -$108.5 million in Q2 2022.
• Average EBT over 5 years is -$36.0 million, with a median of -$29.0 million recorded in 2024.
• Year-over-year, EBT tumbled 42.51% in 2022 and jumped 67.25% in 2023.
• Over 5 years, EBT stood at -$54.5 million in 2022, then surged by 54.09% to -$25.0 million in 2023, then rose by 21.94% to -$19.5 million in 2024, then climbed by 12.76% to -$17.0 million in 2025, then decreased by 7.24% to -$18.3 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$18.3 million in Q2 2026, -$21.9 million in Q1 2026, and -$17.0 million in Q4 2025.